不同剂量阿托伐他汀预处理对经皮冠状动脉介入治疗患者的保护作用
发布时间：2019-08-13 14:30
【摘要】：目的:探讨不同剂量阿托伐他汀预处理对行经皮冠状动脉介入治疗(PCI)的非ST段抬高型急性冠脉综合征(NSTEACS)患者的保护作用。方法:选取2014年1月-2016年4月某院收治的NSTE-ACS患者81例,按随机数字表法分为高剂量组(40例)和低剂量组(41例)。高剂量组患者在PCI术前12～24 h给予阿托伐他汀钙片80 mg,术前2 h再给予40 mg;低剂量组患者在PCI术前12～24 h给予阿托伐他汀钙片10 mg。观察两组患者术后血流储备分数(FFR)、冠脉血流储备分数(CFR)和微循环阻力指数(IMR),比较两组患者手术前后肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)和高敏感性C反应蛋白(hs-CRP)水平。结果:两组患者术后FFR、CFR比较,差异无统计学意义(P0.05);高剂量组患者术后IMR显著低于低剂量组,差异有统计学意义(P0.05)。两组患者术前CK、CK-MB和CRP水平比较,差异无统计学意义(P0.05);术后,低剂量组患者CK-MB和CRP水平显著升高,且显著高于高剂量组,差异均有统计学意义(P0.05);两组患者术后CK水平比较,差异无统计学意义(P0.05)。两组患者均未见明显不良反应发生。结论:在实施PCI术前,对NSTE-ACS患者预先使用高剂量阿托伐他汀(80→40 mg)可显著改善患者微循环障碍,同时抑制炎症反应。
[Abstract]:Objective: to investigate the protective effect of different doses of Atto statins on (NSTEACS) patients with non-ST segment elevation acute coronary syndrome (NSTEACS) treated with percutaneous coronary intervention (PTCA). Methods: from January 2014 to April 2016, 81 patients with NSTE-ACS were randomly divided into high dose group (n = 40) and low dose group (n = 41). Patients in the high dose group were given Atto Vastatin calcium tablets at 12: 24 h before PCI, 80 mg, before operation, and then 40 mg; at 12: 24 h before PCI. The patients in the low dose group were given 10 mg. at 12: 24 h before PCI. The levels of creatine kinase (CK), creatine kinase isoenzyme (CK-MB) and high sensitivity C-reactive protein (hs-CRP) were compared between the two groups before and after operation. The coronary flow reserve fraction (CFR) and microcirculatory resistance index (IMR),) were compared between the two groups. Results: there was no significant difference in postoperative FFR,CFR between the two groups (P 0.05), but the postoperative IMR in the high dose group was significantly lower than that in the low dose group (P 0.05). There was no significant difference in the levels of CK,CK-MB and CRP between the two groups before operation (P 0.05). After operation, the levels of CK-MB and CRP in the low dose group were significantly higher than those in the high dose group (P 0.05). There was no significant difference in the level of CK between the two groups (P 0.05). No obvious adverse reactions were found in both groups. Conclusion: before PCI, the pre-treatment of high dose Atto varastatin (80 mg) can significantly improve the microcirculatory disturbance and inhibit the inflammatory response in patients with NSTE-ACS.
【作者单位】： 解放军第464医院心内科;
【分类号】：R541.4
本文编号：2526185
[Abstract]:Objective: to investigate the protective effect of different doses of Atto statins on (NSTEACS) patients with non-ST segment elevation acute coronary syndrome (NSTEACS) treated with percutaneous coronary intervention (PTCA). Methods: from January 2014 to April 2016, 81 patients with NSTE-ACS were randomly divided into high dose group (n = 40) and low dose group (n = 41). Patients in the high dose group were given Atto Vastatin calcium tablets at 12: 24 h before PCI, 80 mg, before operation, and then 40 mg; at 12: 24 h before PCI. The patients in the low dose group were given 10 mg. at 12: 24 h before PCI. The levels of creatine kinase (CK), creatine kinase isoenzyme (CK-MB) and high sensitivity C-reactive protein (hs-CRP) were compared between the two groups before and after operation. The coronary flow reserve fraction (CFR) and microcirculatory resistance index (IMR),) were compared between the two groups. Results: there was no significant difference in postoperative FFR,CFR between the two groups (P 0.05), but the postoperative IMR in the high dose group was significantly lower than that in the low dose group (P 0.05). There was no significant difference in the levels of CK,CK-MB and CRP between the two groups before operation (P 0.05). After operation, the levels of CK-MB and CRP in the low dose group were significantly higher than those in the high dose group (P 0.05). There was no significant difference in the level of CK between the two groups (P 0.05). No obvious adverse reactions were found in both groups. Conclusion: before PCI, the pre-treatment of high dose Atto varastatin (80 mg) can significantly improve the microcirculatory disturbance and inhibit the inflammatory response in patients with NSTE-ACS.
【作者单位】： 解放军第464医院心内科;
【分类号】：R541.4
【相似文献】
相关期刊论文 前3条
1 黄莉;;氨氯地平联合阿托伐他汀治疗高血压合并冠心病的疗效观察[J];当代医学;2014年12期
2 郑琼;张道进;杨阳;何北海;;急性冠状动脉综合征患者早期应用不同剂量的阿托伐他汀的有效性及安全性对比[J];四川医学;2014年04期
3 苏淑红;王志方;刘志强;;经皮冠状动脉介入治疗术前强化他汀治疗在非ST段抬高的急性冠脉综合征患者中的安全性分析[J];临床医学;2014年05期
相关博士学位论文 前1条
1 康琪;阿托伐他汀对急性心肌梗死大鼠心肌炎症和纤维化反应相关Notch1与TGF-β-Smad信号通路的作用以及对冠心病患者血浆炎性因子Galectin-3作用[D];天津医科大学;2017年
相关硕士学位论文 前3条
1 沈根;强化阿托伐他汀对造影剂急性肾损伤的预防作用[D];宁波大学;2017年
2 李亚如;冠状动脉造影/经皮冠状动脉介入术前强化阿托伐他汀预防对比剂肾病的meta分析[D];山西医科大学;2017年
3 魏倩倩;阿托伐他汀对心肌梗死合并糖尿病患者心率变异性的影响[D];青岛大学;2017年
，本文编号：2526185
本文链接：https://www.wllwen.com/yixuelunwen/xxg/2526185.html
最近更新
教材专著
